Drug Search Results
More Filters [+]

Levodropropizine

Alternative Names: levodropropizine
Latest Update: 2024-10-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Histamine Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Belgium | Brazil | Chile | China | Colombia | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | Greece | Hong Kong | Hungary | India | Indonesia | Italy | Korea | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Spain | Thailand | Turkey | Ukraine | United Arab Emirates | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Dompe
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Levodropropizine

Countries in Clinic: Czech Republic

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Dyspnea

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

INFURO_2023

P2

Unknown Status

Dyspnea

2026-01-01

Recent News Events